{"id":"18f-op-801","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T06:31:58.276Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123342,"model":"claude-sonnet-4-5-20250929"},"description":"18F-OP-801 is an investigational radiopharmaceutical imaging agent being developed by Ashvattha Therapeutics, Inc. Currently in Phase 1 clinical development, this fluorine-18 labeled compound is designed for positron emission tomography (PET) imaging applications, though its specific molecular target and therapeutic focus have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown indication","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT05395624","phase":"PHASE1, PHASE2","title":"Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers","status":"RECRUITING","sponsor":"Ashvattha Therapeutics, Inc.","startDate":"2023-02-02","conditions":"Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD)","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["18F Hydroxyl Dendrimer"],"phase":"phase_1","status":"active","brandName":"18F-OP-801","genericName":"18F-OP-801","companyName":"Ashvattha Therapeutics, Inc.","companyId":"ashvattha-therapeutics-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}